Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 clinical study of ZB001 for the treatment of Thyroid Eye Disease (TED)

Next Previous
Trial Profile

A Phase 1/2 clinical study of ZB001 for the treatment of Thyroid Eye Disease (TED)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Veligrotug (Primary)
  • Indications Graves ophthalmopathy
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Zenas BioPharma

Most Recent Events

  • 03 Nov 2023 According to a Viridian Therapeutics media release, data from this study will be presented at the 2023 Annual Meeting of the American Academy of Ophthalmology (AAO 2023),
  • 07 Sep 2023 According to a Viridian Therapeutics media release, data from this study will be presented at the Annual Meeting of the American Thyroid Association (ATA) to be held September 27-October 1, 2023, in Washington, DC.
  • 07 Sep 2023 According to a Viridian Therapeutics media release, data from this study will be presented at the 41st Annual Meeting of the European Society of Ophthalmic Plastic and Reconstructive Surgery (ESOPRS) to be held September 14-16, 2023, in Naples, Italy.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top